Corrigendum: CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia 2019; 39: 445–458. DOI: 10.1177/0333102418821662

The author regrets that Table 2 published with an incorrect value in the Erenumab column. The correct table is as follows, with the corrected value in bold font:

Table 2.

Attributes of emerging a-CGRP monoclonal antibodies.

	Eptinezumab	Erenumab	Galcanezumab	Fremanezumab
Antibody-IgG	1	2	4	2a
Type	Humanized	Human	Humanized	Humanized
Target	CGRP	CLR/RAMP1	CGRP	CGRP
Bioavailability	100%	40–74%	40%	?
T1/2 (days)	28	28	25–30	45
Production cell line	Yeast	Mammalian (Chinese hamster ovary)	Mammalian (Chinese hamster ovary)	Mammalian (Chinese hamster ovary)
Route frequency	IV/quarterly	SQ/monthly	SQ/monthly	SQ/monthly or quarterly